AHFS Drug Information®

An Evidence-based Foundation for Safe and Effective Drug Therapy

AHFS Drug Information®
2020th Ed.
2020 © American Society of Health-System Pharmacists
Elaine K. Snow, B.S. Pharm.
1-58528-611-7 / 978-1-58528-611-9
ISSN: 8756-6028
Pharmacy/Pharmacology, Drug Information, Neurology, Ophthalmology, Point of Care, Public Health

Description

2020 Updates Include:

  • • Management of opiate use disorder
  • • Multimodal pain management strategies for non-opiate analgesic agents and opiate-sparing drugs
  • • Current best practices for management of pain and sedation in critically ill patients such as the concept of analgosedation and comparisons of various sedative agents used for ICU sedation
  • • Newly published information on breakthrough oncology drugs approved as part of the FDA’s accelerated approval program
  • • Updating of pharmacogenomic considerations related to dosage adjustments (e.g., tamoxifen) or risk of sensitivity reactions (e.g., allopurinol, phenytoin or fosphenytoin)
  • • Expanded information on non-oncology off-label uses (e.g., mycophenolate in treating scleroderma; ketamine use in treatment-resistant depression)
  • • Addition of new therapies for the treatment of seizure disorders, including status epilepticus and intractable childhood epilepsy syndromes
  • • Use of Calcitonin Gene-Related Peptide (CGRP) antagonists in the preventive treatment of migraines
  • • Important changes in management of diabetes, including effects of SGLT2 inhibitors and GLP-1 agonists on cardiovascular risk reduction and beneficial effects on renal function

Special Feature: A discussion of recent evidence questioning aspirin’s role in primary prevention of cardiovascular events in most adults, including the American College of Cardiology and American Heart Association’s positions.

This title updates: Monthly

Doody's Reviews

Doody's Core Titles (DCT)
Essential Purchase Title (EPT)
Specialty Score: 2.87 Health Sciences - Pharmacology/Pharmacy
Go to Doody's Review page

Quotes, Reviews or Testimonials

"This reference is widely used and trusted for its established record in refuting unfounded efficacy claims, its rigorous science-based editorial process, and its independence from the influence of pharmaceutical manufacturers."

-- Jennifer Colon, PharmD, MS, MBA (Temple University School of Pharmacy) - previous edition

"You cannot be a pharmacist without this book. For clinical pharmacists especially it is the standard..."

-- Miriam Klein, Pharm.D. R.Ph. (Woodhull Medical Center) - previous edition

“AHFS Drug Information is by far the most comprehensive and informative drug reference that I use. It offers much more in-depth information and post-marketing [after FDA approval] analysis on drugs.”

-- Jay S. Cohen, M.D., Associate Professor of Family and Preventive Medicine, University of California at San Diego Medical School - previous edition

“There is more in-depth information in AHFS DI, particularly pharmacology and kinetics. At times I especially need the unlabeled uses in AHFS Drug Information to answer questions. Other references don't include as many off-label uses.”

-- Paul Matuschka, Pharm.D., VA Medical Center, Louisville, KY - previous edition

Audience

This reference is intended to shape treatment decisions made by practitioners and clinicians and to influence public and private healthcare policies and decisions. It can be used as a valuable and unbiased pharmaceutical reference by clinical students and practitioners.

Table of Contents


Similar Resources